Pioneering Targeted Delivery of Genetic Medicines
Code Biotherapeutics is a preclinical-stage genetic medicine company developing transformational non-viral delivery of genetic medicines using its proprietary 3DNA® platform. The 3DNA platform is a multivalent synthetic DNA scaffold engineered to overcome key challenges in genetic medicine delivery including dose-related toxicity and immunogenicity. Code Bio's most advanced program targets Duchenne Muscular Dystrophy.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2022
Apr 2021
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
